Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636216 | 0.78 | NCF1 (0.42) | — | |
| SCHEMBL3224012 | 0.68 | XIAP (0.54) | APPHRH4TRPM8KCNH3ALDH1A1 | |
| SCHEMBL21323398 | 0.68 | TDP1 (0.37) | HCAR3APPTRPM8L3MBTL1KCNH3 | |
| SCHEMBL4637203 | 0.68 | MAP4K4 (0.42) | HCAR3AURKAAURKBMAP4K4MEN1 | |
| SCHEMBL12541310 | 0.68 | TDP1 (0.44) | HCAR3APPTRPM8L3MBTL1KCNH3 | |
| SCHEMBL10212545 | 0.67 | HRH4 (0.55) | HRH4 | |
| SCHEMBL15920651 | 0.66 | — | — | |
| SCHEMBL25150667 | 0.65 | NOS3 (0.41) | HCAR3TRPM8KCNH3MEN1ALDH1A1 | |
| SCHEMBL10212536 | 0.65 | HCAR3 (0.38) | HCAR3APPHRH4TRPM8AURKA | |
| SCHEMBL544264 | 0.65 | MAOB (0.39) | HCAR3TRPM8PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110686-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKI KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20110028514-A1 | Azoles as Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-02-03 | — | — | US | disclosed |
| US-7709510-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1931620-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007034252-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1370260-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003090746-A1 | 1,3-THIAZOLES AS LXR MODULATORS IN THE TREATMENT OF CARDIOVASCULAR DISEASES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-06 | — | — | WO | disclosed |
| WO-2002066035-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028514-A1 | Azoles as Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | ME3, ME1, MLYCD | HCAR3 338/4885APP 3826/4885HRH4 2464/4885 |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | HCAR3 563/4885APP 4070/4885HRH4 3073/4885 |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | HCAR3 30/4885APP 4263/4885HRH4 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.